Moosavian Toktam, Moosavian Hamidreza
Pediatric Neurology Department, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Iran J Child Neurol. 2024 Fall;18(4):121-126. doi: 10.22037/ijcn.v18i4.45400. Epub 2024 Sep 29.
Absence epilepsy is one of the most common epileptic syndromes in children, and despite its benign nature, a percentage of these children are drug-resistant. This study presents four cases of drug-resistant absence epilepsy in children who were unresponsive to traditional antiepileptic drugs. The study reports the successful use of Lacosamide as an adjunctive therapy to completely control symptoms and electroencephalogram (EEG) abnormalities. The patients, aged four to ten years, had previously failed treatment with Ethosuximide, Sodium Valproate, Levetiracetam, and Topiramate in various combinations. Lacosamide was initiated at a dose of 10 mg/kg per day in combination with Sodium valproate, resulting in rapid and sustained improvement. The patients remained symptom-free and showed no EEG abnormalities for one to two years. These findings suggest that Lacosamide can be considered a safe add-on drug for refractory absence epilepsy. However, it may be contended that additional confirmatory trials are necessary to investigate the effects of Lacosamide in a larger patient population.
失神癫痫是儿童最常见的癫痫综合征之一，尽管其本质为良性，但仍有一定比例的患儿存在耐药情况。本研究呈现了4例对传统抗癫痫药物无反应的儿童耐药失神癫痫病例。该研究报告了成功使用拉科酰胺作为辅助治疗手段，以完全控制症状和脑电图（EEG）异常。这些年龄在4至10岁的患者此前使用乙琥胺、丙戊酸钠、左乙拉西坦和托吡酯的各种联合治疗均告失败。拉科酰胺以每日10 mg/kg的剂量与丙戊酸钠联合使用，带来了快速且持续的改善。患者在一至两年内保持无症状，且脑电图无异常。这些发现表明，拉科酰胺可被视为难治性失神癫痫的一种安全附加药物。然而，可能有人会认为，有必要进行更多的验证性试验，以研究拉科酰胺在更大患者群体中的效果。
